In the published article, there was an error. The numbers of the concentrations were mistaken.
A correction has been made to Results, Pharmacokinetics of GA metabolites in female and male EHBRs orally treated with GA, Paragraph 7. These sentences previously stated:
“The concentrations of GA and its metabolites 12 h after oral administration of GA in female EHBRs were 3.2 µM of GA, 0.1 µM of 3MGA, 14 µM of 1, 4.3 µM of 2, 6.6 µM of 3, and 166 µM of 4.”
and
“The concentrations of GA and its metabolites 12 h after oral administration of GA in male EHBRs were 2.6 µM of GA, 1.2 µM of 3MGA, 102 µM of 1, 4.1 µM of 2, 1.2 µM of 3, and 198 µM of 4.”
The corrected sentences appear below:
“The concentrations of GA and its metabolites 12 h after oral administration of GA in female EHBRs were 2.7 µM of GA, 0.1 µM of 3MGA, 32 µM of 1, 10 µM of 2, 2.0 µM of 3, and 208 µM of 4.”
and
“The concentrations of GA and its metabolites 12 h after oral administration of GA in male EHBRs were 2.6 µM of GA, 1.6 µM of 3MGA, 177 µM of 1, 8.2 µM of 2, 2.2 µM of 3, and 237 µM of 4.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
kampo medicine, side effect, liquorice, glycyrrhizin, pseudoaldosteronism, sex differences
Citation
Ishiuchi K, Morinaga O, Yoshino T, Mitamura M, Hirasawa A, Maki Y, Tashita Y, Kondo T, Ogawa K, Lian F, Ogawa-Ochiai K, Minamizawa K, Namiki T, Mimura M, Watanabe K and Makino T (2022) Corrigendum: Identification of an alternative glycyrrhizin metabolite causing liquorice-induced pseudohyperaldosteronism and the development of ELISA system to detect the predictive biomarker. Front. Pharmacol. 13:1090327. doi: 10.3389/fphar.2022.1090327
Received
05 November 2022
Accepted
10 November 2022
Published
24 November 2022
Volume
13 - 2022
Edited and reviewed by
Wei Li, Toho University, Japan
Updates
Copyright
© 2022 Ishiuchi, Morinaga, Yoshino, Mitamura, Hirasawa, Maki, Tashita, Kondo, Ogawa, Lian, Ogawa-Ochiai, Minamizawa, Namiki, Mimura, Watanabe and Makino.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Toshiaki Makino, makino@phar.nagoya-cu.ac.jp
†These authors have contributed equally to this work
‡Present address: Kampo Clinical Center, Department of General Medicine, Hiroshima University Hospital, Hiroshima, Japan
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.